Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 960 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 What’s at the Root of Ovarian Cancer? New Study May Have... April 24, 2025 Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... April 7, 2025 Trametinib Is a New Treatment Option for Rare Form of Ovarian... March 10, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Datopotamab Deruxtecan Stealing Strategies from Cancerous T Cells May Boost Immunotherapy Gift Giving During a Pandemic Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib...
